Val Kennedy is a News Editor for Seeking Alpha, a platform focused on financial markets and investment analysis. Val covers a wide range of topics in the biotech and pharmaceutical industries, providing updates on company news, drug approvals, acquisitions, and market trends.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Val Kennedy's coverage primarily focuses on healthcare, pharmaceuticals, and investment analysis within the private sector. She seems to be interested in covering developments such as company announcements, investment analysis, and press releases related to pharmaceutical companies and biotechnology firms.
If you're looking to reach out to Val Kennedy for coverage or pitching a story idea, consider providing insights into new drug approvals by regulatory agencies like FDA or significant business moves within the pharmaceutical industry. Additionally, pitches related to IPOs of healthcare-related companies or changes in key leadership positions within major pharmaceutical firms might also catch her attention.
Val does not appear to have a specific geographic focus but covers developments from various regions. Therefore, she may value global perspectives on trends and events in the healthcare and pharmaceutical sectors.
This information evolves through artificial intelligence and human feedback. Improve this profile .
23andMe (ME) said in an SEC filing that it plans to lay off about 9% of its workforce, or around 75 employees, as part of a company restructuring. Read more here.
By: Val Kennedy
Avrobio (AVRO) has completed the sale of its cystinosis gene therapy program to Novartis (NVS) for $87.5M in cash, which should extend its cash runway into Q4 2024. Read more here.
By: Val Kennedy
Teva Pharmaceutical Industries (TEVA) has agreed to pay $1.41B to settle the State of Kentucky's price-fixing claims against the company. Read more here.
The FDA has expanded its approval of Ironwood Pharmaceuticals' (IRWD) drug Linzess to include the treatment of functional constipation in children and teens. Read more here.
Biogen (BIIB) said that three of its board members will no longer stand for reelection at the company's upcoming annual meeting, which it plans to adjourn until June 26. Read more.
By: Val Kennedy
Lava Therapeutics (LTRX) said that it is discontinuing development of its hematology drug candidate LAVA-051 over competitive concerns and will instead focus on its lead program.
By: Val Kennedy
Biolife4D (SAVU), which has been developing bioengineered human hearts, has upsized its proposed initial public offering to $10M from $8M. Read more here.
BofA Securities has initiated coverage of Oculis (OCS) with a buy rating, citing the market potential of its topical treatment for diabetic macular edema, or DME.
By: Val Kennedy
BTIG has initiated coverage of eye drug developer Viridian Therapeutics (VRDN) with a buy rating, citing its drug candidate for the treatment of thyroid eye disease, or TED.
By: Val Kennedy
Amgen (AMGN) has reportedly hired Moderna's (MRNA) chief medical officer, Paul Burton, as its new chief medical officer. Read more here.
(833) 317-6278 
